Skip to main content
APGE
NASDAQ Life Sciences

Major Shareholder Fairmount Funds Commits to AbbVie Acquisition of Apogee Therapeutics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$132.7
Mkt Cap
$10.018B
52W Low
$34.34
52W High
$133.16
52W Position info
286% above low
Off High info
at 52W high
Rel. Volume info
5.2× avg
Market data snapshot near publication time

APGE has more than doubled off its 52-week low of $34.34 on elevated volume (5.2× avg).

Summary

Fairmount Funds, a major investor in Apogee Therapeutics, has formally agreed to vote its nearly 10% stake in favor of the company's acquisition by AbbVie for $135.11 per share, bolstering the deal's certainty.


Key Events · M&A and Partnerships · APGE

  • Merger Agreement Confirmed

    Apogee Therapeutics will be acquired by AbbVie Inc. for $135.11 per share in cash, as previously announced on June 22, 2026.

  • Major Shareholder Voting Agreement

    Fairmount Funds Management LLC, holding approximately 9.84% of Apogee's common stock, has entered into a voting agreement to support the merger. They committed to vote in favor of the deal and against any alternative transactions.

  • Irrevocable Proxy Granted

    Fairmount Funds granted an irrevocable proxy to AbbVie to ensure their shares are voted for the merger, further solidifying the deal's path to completion.

  • Director Resignation Noted

    Peter Harwin resigned from the Board of Directors on May 11, 2026, which the filing states was not due to any disagreement.


Analysis · APGE · Life Sciences

This Schedule 13D/A confirms the definitive agreement for AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash. Crucially, it discloses that Fairmount Funds Management LLC, a significant shareholder with approximately 9.84% ownership, has entered into a voting agreement to support the merger. This commitment from a major institutional investor significantly de-risks the merger's completion by ensuring a substantial block of votes in favor of the transaction, especially as the stock trades near its 52-week high, reflecting the acquisition premium.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APGE was trading at $132.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $34.34 to $133.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APGE - Latest Insights

APGE
Sep 03, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $135.11
Real-time Price: $135.11 info
Change: $0 (0%) info
Market Cap: $10.223B info
APGE
Aug 11, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $134.69
Real-time Price: $135.11 info
Change: +$0.420 (+0.31%) info
Market Cap: $10.223B info
APGE
Aug 10, 2026, 7:52 AM EDT
Filing Type: 10-Q
Importance Score:
10
Price at Filing: $134.62
Real-time Price: $135.11 info
Change: +$0.486 (+0.36%) info
Market Cap: $10.223B info
APGE
Aug 10, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $134.79
Real-time Price: $135.11 info
Change: +$0.320 (+0.24%) info
Market Cap: $10.223B info
APGE
Aug 06, 2026, 6:31 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $134.27
Real-time Price: $135.11 info
Change: +$0.840 (+0.63%) info
Market Cap: $10.223B info